ABSTRACT Thirteen million cancer deaths and 21.7 million new cancer cases are expected in the world by 2030. Glioblastoma is the most common primary malignant tumor of the central nervous system which is the most lethal type of primary brain tumor in adults with the survival time of 12–15 months after the initial diagnosis. Glioblastoma is the most common and most malignant type of brain tumor, and despite surgery, chemotherapy and radiation treatment, the average survival of patients is about 14 months. The current research showed that the frequency magnetic field (FMF) and static magnetic field (SMF) can influence cancer cell proliferation and coupled with anticancer drugs may provide a new strategy for cancer therapy. At the present study, we investigated the effects of FMF (10 Hz, 50 G), SMF (50 G) and Temozolomide (200 μm) on viability, free radical production, and p53 followed by p53 protein expression in the human glioblastoma cell line (A172) by MTT, NBT, RT-PCR and Western blot. Results showed that the effect of Temozolomide (TMZ) with SMF and FMF together increased the cytotoxicity, free radical production, and p53 followed by p53 protein expression in the human glioblastoma cell line (A172).

中文翻译：

---

频率磁场、静电场和替莫唑胺对人胶质母细胞瘤细胞系 (A172) 活力、自由基产生和基因表达 (p53) 的评估

摘要 到 2030 年，全球预计将有 1300 万癌症死亡和 2170 万新癌症病例。胶质母细胞瘤是中枢神经系统最常见的原发性恶性肿瘤，是成人最致命的原发性脑肿瘤类型，存活时间为 12 – 初步诊断后 15 个月。胶质母细胞瘤是最常见和最恶性的脑肿瘤类型，尽管进行了手术、化疗和放疗，但患者的平均生存期约为 14 个月。目前的研究表明，频率磁场（FMF）和静磁场（SMF）可以影响癌细胞增殖，与抗癌药物联用可能为癌症治疗提供新的策略。在本研究中，我们研究了 FMF（10 Hz，50 G）、SMF（50 G）和替莫唑胺（200 μm）对活力的影响，通过 MTT、NBT、RT-PCR 和蛋白质印迹，在人胶质母细胞瘤细胞系 (A172) 中产生自由基，然后 p53 和 p53 蛋白表达。结果表明，替莫唑胺 (TMZ) 与 SMF 和 FMF 共同作用可增加人胶质母细胞瘤细胞系 (A172) 中的细胞毒性、自由基产生和 p53，继之以 p53 蛋白表达。